

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4483168

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
MELINTA THERAPEUTICS, INC.	06/28/2017

**RECEIVING PARTY DATA**

<b>Name:</b>	SUCHARD SA LLC
<b>Street Address:</b>	C/O OBERLAND CAPITAL 1700 BROADWAY, 37TH FLOOR
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10019

**PROPERTY NUMBERS Total: 33**

Property Type	Number
Patent Number:	7576216
Patent Number:	8299254
Patent Number:	8648196
Patent Number:	8927723
Patent Number:	7728143
Patent Number:	8252813
Patent Number:	8273892
Patent Number:	8648093
Patent Number:	8969569
Patent Number:	9539250
Application Number:	15359734
Patent Number:	8497378
Patent Number:	8871938
Application Number:	14743365
Application Number:	15042886
Application Number:	14744432
Application Number:	14744671
Application Number:	15420739
Application Number:	14775465
Patent Number:	6925394

PATENT

Property Type	Number
Patent Number:	7606670
Patent Number:	7079956
Patent Number:	8374794
Patent Number:	8428884
Patent Number:	6947845
Patent Number:	7666849
Patent Number:	8470990
Patent Number:	8912150
Patent Number:	6638908
Patent Number:	6939848
Patent Number:	6947844
Patent Number:	7504486
Patent Number:	6952650

**CORRESPONDENCE DATA**

**Fax Number:** (415)693-2222

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 4156932000

**Email:** crhem@cooley.com

**Correspondent Name:** COOLEY LLP

**Address Line 1:** 101 CALIFORNIA STREET, 5TH FLOOR

**Address Line 4:** SAN FRANCISCO, CALIFORNIA 94111

**ATTORNEY DOCKET NUMBER:** 324998-108

**NAME OF SUBMITTER:** C. RHEM

**SIGNATURE:** /CR/

**DATE SIGNED:** 06/28/2017

**Total Attachments: 14**

source=Oberland-Melinta - Patent Security Agreement Execution#page1.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page2.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page3.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page4.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page5.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page6.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page7.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page8.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page9.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page10.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page11.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page12.tif  
source=Oberland-Melinta - Patent Security Agreement Execution#page13.tif



PATENT SECURITY AGREEMENT

This Patent Security Agreement is entered into as of June 28, 2017 by and between SUCHARD SA LLC (“Agent”) and MELINTA THERAPEUTICS, INC., a Delaware corporation (“Grantor”).

RECITALS

A. Lender has agreed to make certain advances of money and to extend certain financial accommodation (the “Loans”) to Grantor in the amounts and manner set forth in that certain Loan and Security Agreement by and among the several entities from time to time parties thereto (collectively, referred to as “Lender”), Agent and Grantor, dated as of May 2, 2017 (as the same may be amended, modified or supplemented from time to time, the “Loan Agreement”); capitalized terms used herein are used as defined in the Loan Agreement).

B. Lender is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent a security interest in certain Patents to secure the obligations of Grantor under the Loan Agreement.

C. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, Grantor agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement and the other Loan Documents, Grantor grants and pledges to Agent a security interest in all of Grantor’s right, title and interest in, to and under its Patents (including without limitation those Patents listed on Exhibit A hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof (collectively, the “Patent Collateral”). Notwithstanding the foregoing, the “Patent Collateral” shall not include nonassignable licenses or contracts, which by their terms require the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406, 9407 and 9408 of the UCC).

This security interest is granted in conjunction with the security interest granted to Agent under the Loan Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Grantor does hereby acknowledge and affirm that the rights and remedies of Agent with respect to the security interests in the Patent Collateral granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. Each right, power and remedy of Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Patent Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

Grantor represents and warrants that Exhibit A attached hereto sets forth any and all patent rights in connection to which Grantor has registered or filed an application with the United States Patent and Trademark Office.

This Patent Security Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties have caused this Patent Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:

MELINTA THERAPEUTICS, INC.  
Attention: Paul Estrem, Chief Financial Officer and  
Susan Blum, Assistant Controller  
300 George Street, Suite 301  
New Haven, Connecticut 06511  
Telephone: 312-724-9407 (Mr. Estrem)  
312-962-8246 (Ms. Blum)  
E-mail: pestrem@melinta.com and sblum@melinta.com

GRANTOR:

MELINTA THERAPEUTICS, INC.

By: Paul D. Estrem

Title: Chief Financial Officer

Address of Agent:

SUCHARD SA LLC  
c/o Oberland Capital  
1700 Broadway, 37th Floor  
New York, NY 10019  
Facsimile: (212) 257-5851  
Telephone: (212) 257-5850  
E-mail: ddubinsky@oberlandcapital.com

AGENT:

SUCHARD SA LLC

By: \_\_\_\_\_

Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Patent Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:

MELINTA THERAPEUTICS, INC.  
Attention: Paul Estrem, Chief Financial Officer and  
Susan Blum, Assistant Controller  
300 George Street, Suite 301  
New Haven, Connecticut 06511  
Telephone: 312-724-9407 (Mr. Estrem)  
312-962-8246 (Ms. Blum)  
E-mail: pestrem@melinta.com and sblum@melinta.com

GRANTOR:

MELINTA THERAPEUTICS, INC.

By: \_\_\_\_\_


Title: \_\_\_\_\_

Address of Agent:

SUCHARD SA LLC  
c/o Oberland Capital  
1700 Broadway, 37th Floor  
New York, NY 10019  
Facsimile: (212) 257-5851  
Telephone: (212) 257-5850  
E-mail: ddubinsky@oberlandcapital.com

AGENT:

SUCHARD SA LLC

By:  \_\_\_\_\_

Title: Authorized Signatory

EXHIBIT A

Patents

[See attached.]



## Patent List June 2017

Patent Number	Country	Applicant	Applicant Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
Delafloxacin							
ABT-001	US	Issued	11/191,319	07/28/05	7,576,216 B2	08/18/09	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 C1	US	Issued	12/543,240	08/18/09	8,299,254 B2	10/30/12	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 C2	US	Issued	13/663,601	10/30/12	8,648,196	02/11/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 C3	US	Issued	14/176334	02/10/14	8,927,723	01/06/15	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 CA	Canada	Granted	2575148	07/28/05	2575148	07/17/12	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 DE DV1	Germany	Validated	09163080.6	06/18/09	2100892	04/23/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 DE DV2	Germany	Granted	10187876.7	07/29/05	2305666	06/25/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 EP DV1	Europe	Granted	09163080.6	06/18/09	2100892	04/23/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 EP DV2	Europe	Granted	10187876.7	10/18/10	2305666	06/25/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 ES DIV	Spain	Granted	09163080.6	07/29/05	2100892	04/23/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 ES DIV2	Spain	Granted	10187876.7	07/29/05	2305666	06/25/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 FR DV2	France	Granted	10187876.7	09/29/05	2305666	06/25/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 FR DV1	France	Validated	09163080.6	06/18/09	2100892	04/23/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 GB DV2	United Kingdom	Granted	10187876.7	07/29/05	2305666	06/25/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 GB DV1	United Kingdom	Validated	09163080.6	06/18/09	2100892	04/23/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 HK	Hong Kong	Granted	11110562.4	06/18/09	HK1156311	06/25/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 IT DV2	Italy	Granted	10187876.7	07/29/05	2305666	06/25/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 IT DV1	Italy	Validated	09163080.6	07/29/05	2100892	04/23/14	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 JP	Japan	Granted	2007-523837	07/29/05	5274012	05/24/13	Preparation of Pyridone Carboxylic Antibacterials
ABT-001 MX	Mexico	Issued	MX/1,2007/001134	07/28/05	276491	06/09/10	Preparation of Pyridone Carboxylic Antibacterials
ABT-002	US	Issued	11/245,561	10/07/05	7,728,143	06/01/10	Salt and Crystalline Forms Thereof of a Drug
ABT-002 C	US	Issued	12/701,254	02/05/10	8,252,813	08/28/12	Salt and Crystalline Forms Thereof of a Drug
ABT-002 C2	US	Issued	12/763,476	04/20/10	8,273,892	09/25/12	Salt and Crystalline Forms Thereof of a Drug
ABT-002 C3	US	Issued	13/595,585	08/27/12	8,648,093	02/11/14	Salt and Crystalline Forms Thereof of a Drug
ABT-002 C4	US	Issued	14/175,621	02/07/14	8,969,569	03/03/15	Salt and Crystalline Forms Thereof of a Drug
ABT-002 C7	US	Pending	14/612,879	02/03/15	9,539,250	01/10/17	Salt and Crystalline Forms Thereof of a Drug
ABT-002 CA	Canada	Granted	15/359,734	11/23/16			Salt and Crystalline Forms Thereof of a Drug
ABT-002 EP1	Europe	Granted	2582954	10/07/05	2582954	07/29/14	Salt and Crystalline Forms Thereof of a Drug
ABT-002 EP2	Europe	Pending	15199355.7	10/07/2005	3056492	8/17/2016	Salt and Crystalline Forms Thereof of a Drug
ABT-002 HK2	Hong Kong	Pending	17101093.5	2/1/2017			Salt and Crystalline Forms Thereof of a Drug
ABT-002 JP	Japan	Granted	2007-535819	10/07/05	5294633	06/21/13	Salt and Crystalline Forms Thereof of a Drug
ABT-002 MX	Mexico	Granted	MX/a2007/004111	10/07/05	289460	08/18/11	Salt and Crystalline Forms Thereof of a Drug
ABT-002 MX DIV	Mexico	Granted	MX/a2012/003442	02/21/12	310114	05/31/13	Salt and Crystalline Forms Thereof of a Drug
ABT-003 AL	Albania	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 AT	Austria	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 BA	Bosnia and Herzegovina	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 BE	Belgium	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs

PATENT

REEL: 042854 FRAME: 0761

## Patent List June 2017

Patent Number	Country	Appl. Status	Appl. Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
ABT-003 BG	Bulgaria	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 CA	Canada	Granted	2603783	04/11/06	2603783	11/18/14	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 CH	Switzerland	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 CY	Cyprus	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 CZ	Czech Republic	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 DE	Germany	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 DK	Denmark	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 EE	Estonia	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 EP	Europe	Granted	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 ES	Spain	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 FI	Finland	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 FR	France	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 GB	United Kingdom	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 GR	Greece	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 HR	Croatia	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 HU	Hungary	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 IE	Ireland	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 IS	Iceland	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 IT	Italy	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 JP	Japan	Granted	2008-506637	04/11/06	5284777	06/07/13	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 LI	Liechtenstein	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 LT	Lithuania	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs

PATENT

REEL: 042854 FRAME: 0762

## Patent List June 2017

Patent Number	Country	Appl. Status	Appl. Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
ABT-003 LU	Luxembourg	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 LV	Latvia	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 MC	Monaco	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 ME	Montenegro	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 MK	Macedonia	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 MX	Mexico	Granted	MX/a/2007/012642	04/11/06	299187	05/15/12	Profiles for Poorly Soluble Drugs
ABT-003 NL	Netherlands	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 PL	Poland	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 PT	Portugal	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 RO	Romania	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 RS	Serbia	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 SE	Sweden	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 SI	Slovenia	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 SK	Slovakia	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
ABT-003 TR	Turkey	Validated	06740898.9	04/11/06	EP 1868581	03/14/12	Pharmaceutical Compositions Having Improved Dissolution Profiles for Poorly Soluble Drugs
RIB-063	US	Issued	13/120,278	11/01/11	8,497,378	07/30/13	Process for Making Quinolone Compounds
RIB-063 AU	Australia	Granted	2009297085	09/23/09	2009297085	10/22/15	Process for Making Quinolone Compounds
RIB-063 BR	Brazil	Pending	P10919241-7	09/23/09			Process for Making Quinolone Compounds
RIB-063 CA	Canada	Granted	2738236	09/23/09	2738236	11/15/16	Process for Making Quinolone Compounds
RIB-063 CN	China	Granted	200980138280.X	09/23/09	ZL200980138280.X	08/19/15	Process for Making Quinolone Compounds
RIB-063 CN1	China	Pending	201510401546.2	09/23/09			Process for Making Quinolone Compounds
RIB-063 EP	Europe	Granted	09816565.7	09/23/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 EP 2	Europe	Pending	17163383.7	09/23/09			Process for Making Quinolone Compounds
RIB-063 CH	Switzerland	Granted	09816565.7	09/24/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 DE	Germany	Granted	09816565.7	09/25/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 DK	Denmark	Granted	09816565.7	09/26/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 EP	European Patent Convention	Granted	09816565.7	09/27/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 ES	Spain	Granted	09816565.7	09/28/09	2346855	04/05/17	Process for Making Quinolone Compounds

PATENT

REEL: 042854 FRAME: 0763

## Patent List June 2017

Patent Number	Country	Applicant Status	Applicant Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
RIB-063 FR	France	Granted	09816565.7	09/29/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 GB	United Kingdom	Granted	09816565.7	09/30/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 IE	Ireland	Granted	09816565.7	10/01/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 IT	Italy	Granted	09816565.7	10/02/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 NL	Netherlands	Granted	09816565.7	10/03/09	2346855	04/05/17	Process for Making Quinolone Compounds
RIB-063 HK	Hong Kong	Pending	11109814.2	09/23/09			Process for Making Quinolone Compounds
RIB-063 HK2	Hong Kong	Pending	16101979.5	9/23/2009			Process for Making Quinolone Compounds
RIB-063 IL	Israel	Pending	211845	09/22/09			Process for Making Quinolone Compounds
RIB-063 IN	India	Pending	1315/KOLNP/2011	09/23/09			Process for Making Quinolone Compounds
RIB-063 JP	Japan	Granted	2011-529013	09/23/09	6013734	09/30/16	Process for Making Quinolone Compounds
RIB-063 KR DIV	Korea	Pending	10-2016-7026280	09/23/09			Process for Making Quinolone Compounds
RIB-063 KR DIV	Korea	Pending	10-2017-7008707	09/23/09			Process for Making Quinolone Compounds
RIB-063 MX	Mexico	Granted	MX/a/2011/003122	09/23/09	329985	05/11/15	Process for Making Quinolone Compounds
RIB-063 MX DIV	Mexico	Pending	MX/a/2015/0081	09/23/09			Process for Making Quinolone Compounds
RIB-063 RU	Russia	Granted	2011116052	09/23/09	2546667	04/10/15	Process for Making Quinolone Compounds
RIB-063 SG	Singapore	Granted	2011020732	09/23/09	169803	08/23/16	Process for Making Quinolone Compounds
RIB-063 SG DIV	Singapore	Pending	10201605492-Y	09/29/16			Process for Making Quinolone Compounds
RIB-063C US	US	Issued	13/937,488	09/22/09	8,871,938	10/28/14	Process for Making Quinolone Compounds
RIB-063C2 US	US	Pending	14/743,365	08/18/15			Process for Making Quinolone Compounds
RIB-064 AE	United Arab Emirates	Pending	P477/11	11/12/09			Antimicrobial Compositions
RIB-064 AU	Australia	Granted	20099314072	11/12/09	20099314072	11/03/16	Antimicrobial Compositions
RIB-064 BR	Brazil	Pending	P10921705-3	11/12/09			Antimicrobial Compositions
RIB-064 CA	Canada	Issued	2743419	11/12/09	2743419	02/14/17	Antimicrobial Compositions
RIB-064 CL	Chile	Granted	01121-2011	11/12/09	CL53555	12/14/16	Antimicrobial Compositions
RIB-064 CN	China	Granted	200980145980.1	11/12/09	ZL200980145980.1	07/01/15	Antimicrobial Compositions
RIB-064 CN 2	China	Granted	201410002645.9	11/12/09	ZL201410002645.9	08/24/16	Antimicrobial Compositions
RIB-064 CN 3	China	Pending	201510257557.5	11/12/09			Antimicrobial Compositions
RIB-064 CO	Colombia	Granted	11-071-900	11/12/09	4851	08/26/13	Antimicrobial Compositions
RIB-064 CR	Costa Rica	Granted	2011-0320	11/12/09	3345	03/09/17	Antimicrobial Compositions
RIB-064 DZ	Algeria	Granted	110404	11/12/09	7898	04/30/12	Antimicrobial Compositions
RIB-064 EA	Eurasia	Pending	201170689	11/12/09	25637	01/30/17	Antimicrobial Compositions
RIB-064 EC	Ecuador	Pending	SP-11-11119	11/12/09			Antimicrobial Compositions
RIB-064 EG	Egypt	Pending	736/2011	11/12/09			Antimicrobial Compositions
RIB-064 EP	Europe	Pending	9826758.6	11/12/09			Antimicrobial Compositions
RIB-064 GT	Guatemala	Pending	A-201100119	11/12/09			Antimicrobial Compositions
RIB-064 HK	Hong Kong	Pending	12102144.7	11/12/09			Antimicrobial Compositions
RIB-064 HK2	Hong Kong	Pending	14109793.4	11/12/09			Antimicrobial Compositions
RIB-064 HK3	Hong Kong	Pending	16101991.9	11/12/2009			Antimicrobial Compositions
RIB-064 HN	Honduras	Pending	2011-001294	11/12/09			Antimicrobial Compositions
RIB-064 ID	Indonesia	Pending	W-00201102140	11/12/09			Antimicrobial Compositions
RIB-064 IL	Israel	Granted	212781	11/12/09	212781	03/30/17	Antimicrobial Compositions
RIB-064 IN	India	Pending	2465/KOLNP/2011	11/12/09			Antimicrobial Compositions
RIB-064 JP	Japan	Granted	2011-536469	11/12/09	6063123	12/22/16	Antimicrobial Compositions
RIB-064 JP 3	Japan	Pending	2016-168777	11/12/09			Antimicrobial Compositions

PATENT

REEL: 042854 FRAME: 0764

## Patent List June 2017

Patent Number	Country	Applicant	Applicant Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
RIB-064 KR	Korea	Pending	10-20111-7013641	11/12/09			Antimicrobial Compositions
RIB-064 MA	Morocco	Granted	PV/33932	11/12/09	32931	01/02/12	Antimicrobial Compositions
RIB-064 MX	Mexico	Granted	MX/a/2011/005117	11/12/09	327684	02/09/15	Antimicrobial Compositions
RIB-064 MY	Malaysia	Pending	P/2011002096	11/12/09			Antimicrobial Compositions
RIB-064 MY DIV	Malaysia	Pending	P/2015002638	11/12/09			Antimicrobial Compositions
RIB-064 NI	Nicaragua	Pending	2011-000097	11/12/09			Antimicrobial Compositions
RIB-064 NZ	New Zealand	Granted	593345	11/12/09	893345	07/30/13	Antimicrobial Compositions
RIB-064 PE	Peru	Granted	001038-2011/DIN	11/12/09	7756	02/05/16	Antimicrobial Compositions
RIB-064 PE	Peru	Pending	002523-2015	11/12/09			Antimicrobial Compositions
RIB-064 PH	Philippines	Allowed	1-2011-500932	11/12/09			Antimicrobial Compositions
RIB-064 SG	Singapore	Granted	201103403-0	11/12/09	171235	06/24/15	Antimicrobial Compositions
RIB-064 SV	El Salvador	Published	2011003907	11/12/09			Antimicrobial Compositions
RIB-064 UA	Ukraine	Granted	201107519	11/12/09	102709	08/12/13	Antimicrobial Compositions
RIB-064 US CON	US	Pending	15/042886	02/12/16	2016/0235736		Antimicrobial Compositions
RIB-064 VN	Vietnam	Pending	1-2011-01509	11/12/09			Antimicrobial Compositions
RIB-064 ZA	South Africa	Granted	2011/04108	11/12/09	2011/04108	09/26/12	Antimicrobial Compositions
RIB-078 AR	Argentina	Pending	14/744.432	06/19/15	2015/0366857		Antimicrobial Compositions with Effervescent Agents
RIB-078 AU1	Argentina	Pending	P150101976	06/19/15			Antimicrobial Effervescent Formulator
RIB-078 AU1	Australia	Pending	2015276954	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 BO	Bolivia	Pending	SP-0129-2015	06/16/15			Antimicrobial Effervescent Formulator
RIB-078 BR1	Brazil	Pending	BR112016029761-0	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 CA1	Canada	Pending	2952950	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 CL1	Chile	Pending	03273-2016	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 CN1	China (People's Republic)	Pending	201580044451.8	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 CO1	Colombia	Published	NC2016/0006106	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 CR1	Costa Rica	Pending	2016-0592	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 EA1	Eurasian Patent Organization	Pending	201692532	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 EC1	European Patent Convention	Published	HEPL-2016-95540	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 EP1	Convention	Published	15810507.2	06/19/15	3157510		Antimicrobial Compositions with Effervescent Agents
RIB-078 GC	GC	Pending	29581	06/18/15			Antimicrobial Effervescent Formulator
RIB-078 GT1	Guatemala	Pending	A-2016-000261	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 HN1	Honduras	Pending	HN/P/2016-002686	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 IL1	Israel	Published	249622	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 JP1	Japan	Pending	2016-574040	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 MX1	Mexico	Pending	MX/a/2016/017350	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 NI1	Nicaragua	Published	2016-000179	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 NZ1	New Zealand	Pending	727638	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 PE1	Peru	Pending	002748-2016	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 PH1	Philippines	Pending	1/2016/502548	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 SV1	El Salvador	Pending	20160021088	06/19/15			Antimicrobial Compositions with Effervescent Agents
RIB-078 TW	Taiwan	Pending	104119676	06/18/15			Antimicrobial Effervescent Formulator

PATENT

REEL: 042854 FRAME: 0765

## Patent List June 2017

Patent Number	Country	Appl. Status	Appl. Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
RIB-078 UY	Uruguay	Pending	36,184	06/20/15			Antimicrobial Effervescent Formulator
RIB-078 VN1	Vietnam	Pending	1-2017-00201	42174			Antimicrobial Compositions with Effervescent Agents
RIB-080 AR	Argentina	Pending	P150101977	06/19/15			Methods for Treating Infections
RIB-080 AU1	Australia	Pending	2015276911	06/19/15			Methods for Treating Infections
RIB-080 BO	Bolivia	Pending	SP-0127-2015	06/16/15			Methods for Treating Infections
RIB-080 BR1	Brazil	Pending	BR112016029896-9	06/19/15			Methods for Treating Infections
RIB-080 CA1	Canada	Pending	2952955	06/19/15			Methods for Treating Infections
RIB-080 CL1	Chile	Pending	03271-2016	06/19/15			Methods for Treating Infections
RIB-080 CN1	China (People's Republic)	Pending	201580044477.2	06/19/15			Methods for Treating Infections
RIB-080 CR1	Costa Rica	Pending	2016-0591	06/19/15			Methods for Treating Infections
RIB-080 EA1	Eurasian Patent Organization	Pending	201692531	06/19/15			Methods for Treating Infections
RIB-080 EC1	Ecuador	Published	IEPI-2016-95557	06/19/15			Methods for Treating Infections
RIB-080 EP1	European Patent Convention	Published	15810585.8	06/19/15	3157633		Methods for Treating Infections
RIB-080 GC	GC	Pending	29580	06/18/15			Methods for Treating Infections
RIB-080 GT1	Guatemala	Pending	A-2016-000260	6/19/2015			Methods for Treating Infections
RIB-080 IL1	Israel	Published	249616	6/19/2015			Methods for Treating Infections
RIB-080 JP1	Japan	Pending	2016-574152	6/19/2015			Methods for Treating Infections
RIB-080 MX1	Mexico	Pending	MX/a/2016/017348	6/19/2015			Methods for Treating Infections
RIB-080 NI1	Nicaragua	Published	2016-000180	6/19/2015			Methods for Treating Infections
RIB-080 NZ1	New Zealand	Pending	72763	6/19/2015			Methods for Treating Infections
RIB-080 PH1	Philippines	Pending	1/2016/502547	6/19/2015			Methods for Treating Infections
RIB-080 SV1	El Salvador	Published	20160021087	6/19/2015	2016005348		Methods for Treating Infections
RIB-080 UY	US	Pending	14/744,671	06/19/15	2015/0366858		Methods for Treating Infections
RIB-080 UY	Uruguay	Pending	36,183	06/22/15	196		Methods for Treating Infections
RIB-080 TW	Taiwan	Pending	104119696	06/18/15	201605447		Methods for Treating Infections
RIB-080 VN1	Vietnam	Pending	1-2017-00202	6/19/2015			Methods for Treating Infections
RIB-081 US3	US	Pending	15/420739	01/31/17			Crystalline Forms of D-Glucitol, 1-Deoxy-1-(Methylamino)-, 1-(Amino-3,5-Difluoropyridin-2-Yl)-8-Chloro-6-Fluoro-1,4-Dihydro-7-(3-Hydroxyazetidin-1-Yl)-4-Oxo-3-Quinolincarboxylate
RIB-082 AE	United Arab Emirates	Pending	P1258/15	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 AR	Argentina	Pending	P140101219	03/17/14	AR095594		Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 AU	Australia	Pending	2014239965	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 BR	Brazil	Pending	BR112015023044-0	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 CA	Canada	Pending	2904387	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics

PATENT

REEL: 042854 FRAME: 0766

## Patent List June 2017

Patent Number	Country	Appln Status	Appln Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
RIB-082 CL	Chile	Pending	02759-2015	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 EP	Europe	Pending	14768456.7	03/14/14	2969004		Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 HK	Hong Kong	Pending	16107660.6	03/15/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 IL	Israel	Pending	241113	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 JP	Japan	Pending	2016-502372	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 KR	Korea	Pending	10-2015-7029301	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 MX	Mexico	Pending	MX/a/2015/011760	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 TR	Turkey	Pending	2015/14167	03/14/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 US	US	Pending	14/775465	09/11/15	2016/0058750		Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 GC	GC	Pending	26770	03/16/14			Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 TW	Taiwan	Pending	103109491	03/14/14	201513862		Methods of treating infections in overweight and obese patients using antibiotics
RIB-082 VE	Venezuela	Pending	000362-2014	03/14/14	560		Methods of treating infections in overweight and obese patients using antibiotics

PATENT

REEL: 042854 FRAME: 0767

## Patent List June 2017

Patent Number	Country	Appl. Status	Appl. Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
<b>Platform IP</b>							
MRC-001	US	Issued	09/904,779	07/13/01	6,925,394	08/02/05	Crystal Structure of the 30S Ribosome and Its Use
MRC-001 CIP	US	Issued	09/953,807	09/17/01	7,606,670	10/20/09	Crystal Structure of the 30S Ribosome and Its Use
MRC-002 CIP	US	Issued	09/953,814	09/17/01	7,079,956	07/18/06	Crystal Structure of Antibiotics Bound to the 30S Ribosome and Its Use
RIB-016C	US	Issued	12/072,980	02/29/08	8,374,794	02/12/13	Protein Synthesis Modulators
RIB-019C	US	Issued	12/074,200	02/29/08	8,428,884	04/23/13	Protein Synthesis Modulators
MRC-001 EP	Europe	Granted	01306060.3	07/13/01	1,172,374	11/22/06	Crystal Structure of the 30S Ribosome and Its Use
MRC-001 GB	U.K.	Validated	1306060.3	07/13/01	1,172,374	11/22/06	Crystal Structure of the 30S Ribosome and Its Use
MRC-002 GB	U.K.	Granted	0117142.0	07/14/01	2368067	11/11/04	Crystal Structure of Antibiotics Bound to the 30S Ribosome and Its Use
RIB-005CP	US	Issued	10/211,931	08/02/02	6,947,845	09/20/05	Method of Identifying Molecules that Bind to the Large Ribosomal Subunit
RIB-005CPC	US	Issued	11/067,522	02/25/05	7,666,849	02/23/10	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005CPC2	US	Issued	12/645,877	12/23/09	8,470,990	06/25/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005CPC3	US	Issued	13/924,155	06/21/13	8912150	12/16/14	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005SCP EP	Europe	Granted	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP AT	Austria	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP BE	Belgium	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP CZ	Czech Republic	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP DK	Denmark	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP EE	Estonia	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors

PATENT

REEL: 042854 FRAME: 0768



## Patent List June 2017

Patent Number	Country	Appl. Status	Appl. Number	Filing or Priority Date	Patent or Publication Number	Issue or Grant or Publication Date	Title
RIB-005 CP FI	Finland	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP FR	France	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP DE	Germany	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP GR	Greece	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP IE	Ireland	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP IT	Italy	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP LI	Liechtenstein	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP LU	Luxembourg	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP NL	Netherlands	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP ES	Spain	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP SE	Sweden	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP CH	Switzerland	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005 CP GB	United Kingdom	Validated	02255442.2	08/02/02	1,308,457	12/04/13	Ribosome Structure and Protein Synthesis Inhibitors
RIB-001	US	Issued	09/635,708	08/09/00	6,638,908	10/28/03	Crystals of the Large Ribosomal Subunit
RIB-001 C	US	Issued	10/391,491	03/17/03	6,939,848	09/06/05	Crystals of the Large Ribosomal Subunit
RIB-001 CIP	US	Issued	09/922,251	08/03/01	6,947,844	09/20/05	Modulators of Ribosomal Function and Modulators Thereof
RIB-001 DV	US	Issued	10/391,289	03/17/03	7,504,486	03/17/09	The Determination and Uses of Atomic Structures of Ribosomes and Ribosomal Subunits and their Ligand Complexes
RIB-001CP EP	Europe	Granted	01306825.9	08/09/01	1188769 B1	05/24/06	Ribosome Structure and Protein Synthesis Inhibitors
RIB-001CP GB	U.K.	Validated	1306825.9	08/09/01	1188769	05/24/06	Ribosome Structure and Protein Synthesis Inhibitors
RIB-001CP JP	Japan	Granted	2001-317-401	08/08/01	3836702	10/25/06	Ribosome Structure and Protein Synthesis Inhibitors
RIB-005	US	Issued	10/072,634	02/08/02	6,952,650	10/04/05	Modulators of Ribosomal Function and Identification Thereof

PATENT